Compass Therapeutics Corp (CMPX): יחס חוב לטווח ארוך להון

Compass Therapeutics (CMPX) faces threats due to high development costs and testing uncertainty, with the indicator standing at 0.05. The price action for the company available on the GURU.Markets chart complements data regarding the expansion of programs to create complex tumor medications. Management, consisting of experts and scientists, effectively coordinates a portfolio of innovative antibodies for oncology treatment.

This indicator assesses long-term financial stability by comparing liabilities with maturities exceeding one year against total equity to determine the degree of debt load. The trend of the long-term debt-to-equity ratio reflects the balance between debt financing and investment, which for Compass Therapeutics (CMPX) is confirmed by the absence of asset depreciation and planned laboratory utilization without excessive leverage.